Overview


According to FutureWise analysis the market for Sulphonamides in 2023 is US$ 0.11 billion, and is expected to reach US$ 0.16 billion by 2031 at a CAGR of 4.70%.

Sulfonamides, also known as sulfa drugs or sulpha drugs, are organic sulfur compounds that contain the radical SO2NH2 (the amide of sulfonic acid). These are the first anti-microbial drugs developed for treating bacterial infections in humans and animals. The sulfonamides interfere with the synthesis of folic acid in bacterial cells by inhibiting the enzyme dihydropteroate synthetase, which competes with para amino benzoic acid (PABA). Folic acid is a precursor to ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) in bacterial cells. Since sulfonamides limit bacterial growth, they are considered bacteriostatic agents. A few sulfonamides are very water-soluble such as sulfisoxazole (sulfafurazole) and sulfasomidine, which are rapidly excreted through the urinary tract (more than 90% in 24 hours) primarily in an unchanged drug form; because of this pharmacokinetic property, these sulfonamides are primarily used to treat urinary tract infections (UTI's). Moreover, some sulfonamide derivatives, such as sulfaguanidine, are insoluble in nature, so they cannot be absorbed from the gastro intestinal tract (less than 5%), so they are used to treat ulcerative colitis. Several people are allergic to sulfa drugs, so sulfonamides are prescribed with caution. Among the potential side effects of sulfonamides are urinary tract disorders, haemopoietic disorders, hypersensitivity reactions, and porphyria.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Sulphonamides Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Sulphonamides Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Abbott Laboratories
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bayer AG
  • GlaxoSmithKline plc.
  • King Pharmaceuticals, Inc.
  • Mylan Pharmaceuticals
  • Novartis International AG
  • Pfizer, Inc.
  • Par Pharmaceutical, Inc.
  • Roche Holding AG
  • Sanofi Aventis
  • Stiefel Laboratories, Inc.
  • Teva Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type of Administration

  • Oral
  • Orally Absorbable Sulfonamide
  • Short Acting (sulafadiazine, sulfacytine, sulfamethizole, sulfisoxazole)
  • Intermediate Acting (sulfamethoxazole, sulfmoxole)
  • Long Acting (sulfadoxine, sulfamethopyrazine)
  • Orally Non Absorbable Sulfonamide (sulfasalzine, osalazine)
  • Topical Agents (Silver sulfadiazine, sulfacetamide, mafenide)

By Type of Therapeutic Use

  • Skin Infections
  • Gastro Intestinal Tract (GIT) Infection
  • Meningitis
  • Urinary Tract Infection (UTI) Infection
  • Respiratory Tract Infection (RTI)
  • Leprosy
  • Bowel Disinfections
  • Malaria
  • Nocardiosis

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Sulphonamides Market By Type of Administration, By Type of Therapeutic Use and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Sulphonamides Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Sulphonamides Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Sulphonamides Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Sulphonamides Market, By Type of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Orally Absorbable Sulfonamide
        3. Short Acting (sulafadiazine, sulfacytine, sulfamethizole, sulfisoxazole)
        4. Intermediate Acting (sulfamethoxazole, sulfmoxole)
        5. Long Acting (sulfadoxine, sulfamethopyrazine)
        6. Orally Non Absorbable Sulfonamide (sulfasalzine, osalazine)
        7. Topical Agents (Silver sulfadiazine, sulfacetamide, mafenide)

  • 8.   Sulphonamides Market, By Type of Therapeutic Use Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Skin Infections
        2. Gastro Intestinal Tract (GIT) Infection
        3. Meningitis
        4. Urinary Tract Infection (UTI) Infection
        5. Respiratory Tract Infection (RTI)
        6. Leprosy
        7. Bowel Disinfections
        8. Malaria
        9. Nocardiosis

  • 9.   North America Sulphonamides Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Sulphonamides Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Sulphonamides Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Sulphonamides Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Sulphonamides Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Abbott Laboratories
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Boehringer Ingelheim Pharmaceuticals, Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bayer AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. GlaxoSmithKline plc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. King Pharmaceuticals, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Mylan Pharmaceuticals
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Novartis International AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Pfizer, Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Par Pharmaceutical, Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Roche Holding AG
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Sanofi Aventis
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Stiefel Laboratories, Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Teva Pharmaceuticals
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients